Isoptin

Cluster Headache, prophylaxis of Cluster headaches, Angina, Unstable + 7 more

Treatment

3 FDA approvals

20 Active Studies for Isoptin

What is Isoptin

Verapamil

The Generic name of this drug

Treatment Summary

Verapamil is a type of medication that blocks calcium from entering the cells in the body. It was first introduced in the 1960s and is used to treat high blood pressure, heart arrhythmias, and angina. Verapamil is a non-dihydropyridine calcium channel blocker, which means it is a different type of medicine than drugs like diltiazem and flunarizine. It is made up of two different components, called enantiomers, which work differently and are metabolized at different rates.

Calan

is the brand name

image of different drug pills on a surface

Isoptin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Calan

Verapamil

1984

357

Approved as Treatment by the FDA

Verapamil, also called Calan, is approved by the FDA for 3 uses which include Atrial Fibrillation or Flutter and Hypertensive disease .

Atrial Fibrillation or Flutter

Used to treat Atrial Fibrillation or Flutter in combination with Digitoxin

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Trandolapril

Heart Rate

Used to treat Heart Rate in combination with Digitoxin

Effectiveness

How Isoptin Affects Patients

Verapamil is a drug that helps regulate heart rhythm, reduce chest pain, and lower blood pressure. The regular form of this drug needs to be taken 3-4 times per day, but there is an extended-release version which can be taken once a day. Verapamil has a negative effect on the heart's ability to contract, so it should not be used by people with severe heart problems such as left ventricular dysfunction or hypertrophic cardiomyopathy.

How Isoptin works in the body

Verapamil blocks the flow of calcium into certain cells, including those found in the heart and the blood vessels. This reduces how hard the heart needs to work and how much pressure the blood vessels need to endure, lowering both blood pressure and levels of angina. It also slows down the electrical activity of the heart, making it beat more slowly and helping to regulate an irregular heart rate. The exact way it works to treat cluster headaches is unknown, but it is thought to be related to blocking other types of calcium channels and potassium channels, as well as affecting adrenaline receptors.

When to interrupt dosage

The indicated dosage of Isoptin is contingent upon the diagnosed condition, such as Tachycardia, Ventricular, Unstable Angina Pectoris and Vasospastic Angina. The magnitude of dosage deviates as per the administration approach indicated in the table underneath.

Condition

Dosage

Administration

Vasospastic Angina

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Angina, Stable

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Heart Rate

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

prophylaxis of Cluster headaches

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Angina, Unstable

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Cluster Headache

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Hypertensive disease

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Tachycardia, Ventricular

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Tachycardia, Supraventricular

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Atrial Fibrillation or Flutter

180.0 mg, 240.0 mg, , 120.0 mg, 360.0 mg, 100.0 mg, 200.0 mg, 300.0 mg, 80.0 mg, 2.4 mg, 2.5 mg/mL, 40.0 mg, 160.0 mg, 5.0 mg/mL, 10.0 mg/mL

Oral, , Tablet, extended release, Tablet, extended release - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Warnings

Isoptin Contraindications

Condition

Risk Level

Notes

Atrioventricular Block

Do Not Combine

Ventricular Tachycardia

Do Not Combine

Atrial Fibrillation

Do Not Combine

Shock, Cardiogenic

Do Not Combine

accessory bypass tract

Do Not Combine

Heart Failure

Do Not Combine

Pulse Frequency

Do Not Combine

Sick Sinus Syndrome

Do Not Combine

Bradycardia

Do Not Combine

Hypotension

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Verapamil may interact with Pulse Frequency

There are 20 known major drug interactions with Isoptin.

Common Isoptin Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Verapamil.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Verapamil.

Acepromazine

Major

Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Verapamil.

Alfuzosin

Major

Verapamil may increase the hypotensive activities of Alfuzosin.

Isoptin Toxicity & Overdose Risk

The lowest toxic dose of verapamil for women is 14.4 mg/kg and for men is 3.429 mg/kg. The lethal dose in rats is 150 mg/kg and in mice is 163 mg/kg. If someone overdoses on verapamil, there is no specific antidote. Treatment focuses on managing the symptoms such as low blood pressure, slow heartbeat, and irregular heart rhythm. Severe cases may require intravenous calcium, atropine, or other drugs to support the heart. If the overdose involved a sustained-release formulation, the person should be monitored closely for at least 48 hours.

image of a doctor in a lab doing drug, clinical research

Isoptin Novel Uses: Which Conditions Have a Clinical Trial Featuring Isoptin?

34 active clinical trials are currently evaluating the possibility of employing Isoptin as a treatment option for Chronic Stable Angina Pectoris, Tachycardia, Ventricular and Paroxysmal Supraventricular Tachycardia (PSVT).

Condition

Clinical Trials

Trial Phases

Cluster Headache

2 Actively Recruiting

Phase 1, Phase 2

Heart Rate

0 Actively Recruiting

Tachycardia, Supraventricular

1 Actively Recruiting

Phase 2

Angina, Unstable

1 Actively Recruiting

Not Applicable

prophylaxis of Cluster headaches

0 Actively Recruiting

Vasospastic Angina

1 Actively Recruiting

Phase 2, Phase 3

Angina, Stable

0 Actively Recruiting

Atrial Fibrillation or Flutter

0 Actively Recruiting

Tachycardia, Ventricular

0 Actively Recruiting

Hypertensive disease

37 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Isoptin Reviews: What are patients saying about Isoptin?

5

Patient Review

7/11/2017

Isoptin for Cluster Headache Prevention

Isoptin really has helped to reduce the intensity of my cluster headaches. I still get them occasionally, but they're nowhere near as bad as they used to be.

5

Patient Review

9/28/2008

Isoptin for High Blood Pressure

4

Patient Review

3/17/2015

Isoptin for Type of Angina Where Chest Pain Occurs at Rest

For me, this medication caused some allergic reactions.

3.7

Patient Review

3/2/2010

Isoptin for High Blood Pressure

I've been taking Verapamil for 15 years with no side effects. I take 240 mg daily to keep my blood pressure in check and it does a great job!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about isoptin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When should you take isoptin?

"Take Isoptin tablets two or three times daily, or Isoptin SR tablets once or twice daily as directed by physician. Swallow tablets whole with a full glass of water."

Answered by AI

What is isoptin used for?

"The drugs Isoptin and Isoptin SR are used to treat high blood pressure and angina. Isoptin is also used to treat irregular heartbeats."

Answered by AI

Is isoptin a beta blocker?

"Isoptin SR is a type of calcium channel blocker that is used to treat hypertension (high blood pressure), angina (chest pain), and certain heart rhythm disorders. The brand name Isoptin SR is no longer available in the United States, but generic versions may be."

Answered by AI

What is the generic name of isoptin?

"This medication is a calcium channel blocker used to treat high blood pressure and angina. It may be used alone or with other medicines.

The name of this medication is Verapamil and it is taken orally. It is a calcium channel blocker used to treat high blood pressure and angina and can be used alone or with other medications."

Answered by AI

Clinical Trials for Isoptin

Image of Vanderbilt University Medical Center in Nashville, United States.

2-HOBA for Salt Sensitivity of Blood Pressure

18+
All Sexes
Nashville, TN

Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+). This trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks. This phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.

Phase 2
Waitlist Available

Vanderbilt University Medical Center

Image of UPMC Magee Womens Hospital in Pittsburgh, United States.

Mobile Health Program for High Blood Pressure After Preeclampsia

18+
Female
Pittsburgh, PA

Strategies targeted to optimize hypertension (HTN) control for midlife women after hypertensive disorders of pregnancy (HDP) have not been studied, despite evidence of a critical need. This proposal targets the 10-20 years postpartum as a key time when women have subclinical cardiovascular (CV) sequelae of uncontrolled HTN and are primed for CV prevention interventions. Before proceeding with large-scale intervention trials of a home blood pressure monitoring (HBPM) and coaching intervention following HDP, further pilot testing is necessary. The overarching hypothesis of this proposal is that a new monitoring and treatment paradigm utilizing HBPM combined with a virtual coaching intervention would be better than standard of care for mid-life women with prior HDP who develop HTN. Women will be assigned in an unblinded manner to the intervention or standard of care control group.

Waitlist Available
Has No Placebo

UPMC Magee Womens Hospital

Malamo Countouris, MD, MS

Image of UCSF Medical Center at Parnassus in San Francisco, United States.

Blood Pressure Monitoring for Atrial Fibrillation

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if screening for atrial fibrillation (AFib), a common irregular heart rhythm, through daily home blood pressure monitoring will decrease the time to atrial fibrillation diagnosis in older adults with hypertension. The main question it aims to answer is: \-- Does introducing screening for AFib using a blood pressure monitor with AFib detection technology decrease time to AFib diagnosis in patients with high blood pressure, compared to usual care using a conventional home blood pressure monitor with no AFib detection? Participants will participate in two phases of the study: (1) clinical trial and (2) the registry. During the 6-month clinical trial period, participants will be asked to: * Take blood pressure measurements twice daily * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take blood pressure measurements twice daily * Answer monthly mobile app-based surveys Researchers will compare standard blood pressure measurements and AFib screening blood pressure measurements to see if there is a difference in the time to AFib diagnosis and other cardiovascular events. Participants will participate in two phases of the study: (1) trial and (2) the registry. During the 6-month trial period, participants will be asked to: * Take daily blood pressure measurements * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take daily blood pressure measurements * Answer monthly mobile app-based surveys

Waitlist Available
Has No Placebo

UCSF Medical Center at Parnassus

Gregory M Marcus, MD, MAS

Omron Healthcare Co., Ltd.

Image of Hāmākua-Kohala Health Center in Honokaa, United States.

Produce Prescription for High Blood Pressure

18+
All Sexes
Honokaa, HI

This multi-site randomized controlled trial uses a community-based approach to evaluate a Food as Medicine program for Native Hawaiian and Pacific Islander (NHPI) adults in Hawaii who have high blood pressure and difficulty affording healthy food. The study has two main goals: (1) to implement a produce prescription program and see if adding personal support from Community Health Workers (CHW) improves blood pressure among other health outcomes, and (2) to determine the program's cost-effectiveness. The study will take place across three Federally Qualified Health Centers in Hawaii. Produce prescription program participants at each site will receive $100 per month, either in the form of produce boxes or monthly vouchers to purchase fruits and vegetables, for 12 months (totaling $1200). In past studies, personal challenges (e.g., lack of transportation, lack of cooking skills) have made it difficult for participants to use the vouchers and/or the purchased produce. In other food as medicine interventions, participants have similarly faced various personal, social, and environmental barriers that limit the program's efficacy. To help participants navigate through these challenges, the investigators want to test adding 1-on-1 support from a CHW throughout the program. Other studies have found that health interventions delivered by CHWs have been effective in reducing blood pressure, blood glucose and weight, especially among vulnerable populations, such as NHPIs and those with food insecurity. The CHWs in this study will receive a training using a curriculum tailored specifically to their community and that is in alignment with the Pilinahā: The Four Connections Framework, which focuses on key connections that Indigenous people seek to attain health and can be employed to overcome health disparities. To test the effectiveness of the added CHW support, there will be two groups of participants: Group 1 (Intervention) will receive the monthly produce prescription ($100 vouchers or produce box) plus meet with a CHW every two months for support with program challenges. Group 2 (Control) will receive the same monthly produce prescription, but will not have meetings with a CHW. The investigators want to see if the added support from CHWs leads to better blood pressure results, among other health outcomes. Upon providing informed consent and enrolling into the program, produce prescription program participants will: * Attend 5 study visits over the one year program. These happen at the start, and then at 3, 6, 9, and 12 months. * Complete health checks at the first visit. This includes getting a home blood pressure monitor and learning about heart health and nutrition. Staff will measure height, weight, waist size, and blood pressure. * Answer surveys about their demographic background, health habits, diet, and culture. * Receive $100 in vouchers every month for 12 months to redeem for fruits and vegetables at a local retailer. * Group 1 will additionally meet with a CHW every two months for 1-on-1 support with any challenges related to the program. * Group 2 will receive monthly reminders to use their vouchers but no CHW meetings. After the program ends, researchers will analyze the financial value of the intervention. This involves calculating the total cost to run the program (including vouchers, CHW training and salaries, and administrative costs) and comparing it to potential savings in healthcare costs. By looking at improvements in blood pressure, researchers can estimate how many heart-related health problems were prevented and how much money was saved on medical care.

Waitlist Available
Has No Placebo

Hāmākua-Kohala Health Center (+2 Sites)

Have you considered Isoptin clinical trials?

We made a collection of clinical trials featuring Isoptin, we think they might fit your search criteria.
Go to Trials
Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Have you considered Isoptin clinical trials?

We made a collection of clinical trials featuring Isoptin, we think they might fit your search criteria.
Go to Trials
Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Recruiting
Has No Placebo

U Health (+5 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Isoptin clinical trials?

We made a collection of clinical trials featuring Isoptin, we think they might fit your search criteria.
Go to Trials